

[ABSTRACT]

The present disclosure relates to a phosphate salt of 1-((3S,4R)-3-((2-
((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-
fluoropiperidin-1-yl)prop-2-en-1-one, a crystalline form thereof and a method for
5 preparation thereof. The phosphate salt and crystalline form have low
hygroscopicity compared to the free base and is improved in stability and
solubility, thereby being suitable for pharmaceutical use.

In addition, the method for preparing the phosphate salt and crystalline
form according to the present disclosure has the advantage that mass
10 production is made possible and the safety of the preparation process is
improved by using safer materials than the reactants used in conventional
preparation methods.